New drug cocktail aims to soothe ICU delirium and prevent breathing tubes
NCT ID NCT07377981
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a combination of two sedatives, esketamine and dexmedetomidine, can better control agitation and shorten delirium in intensive care unit (ICU) patients who are on non-invasive breathing support. The trial will enroll 388 adults with hyperactive delirium and compare the drug combo to standard care. The goal is to see if this approach reduces the need for breathing tubes and speeds recovery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
esketamine combined with dexmedetomidine
What this could lead to
If it works, this could offer a safer, more effective way to manage severe agitation and delirium in ICU patients, potentially reducing the need for breathing tubes.
What could go wrong
This is a single-blind, phase 4 trial with 388 participants, so results may not apply to all ICU patients. The drug combo may cause side effects like sedation or breathing problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANALGESIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••